Metal complexes bearing EGFR-inhibiting ligands as promising anticancer agents

Area of Science:

• Medicinal Chemistry
• Oncology
• Materials Science

Background:

• Epidermal growth factor receptor (EGFR) overexpression is common in solid tumors, correlating with poor prognosis.
• EGFR tyrosine kinase inhibitors (TKIs) are widely used but face challenges including drug resistance, poor tumor accumulation, and side effects.
• Metal complexes present alternative anticancer mechanisms distinct from traditional TKIs.

Purpose of the Study:

• To review metal-EGFR-TKI complexes developed over the last 15 years.
• To summarize the mechanisms of action for these metal complexes.
• To highlight the advantages of metal-based EGFR-TKI strategies in cancer treatment.

Main Methods:

• Literature review of metal complexes targeting EGFR-TKIs.
• Analysis of reported mechanisms of action for various metal centers (Ru, Pt, Au, Co, Rh, Fe, Ga).
• Summary of advantages including multi-targeting, overcoming resistance, prodrug strategies, enhanced efficacy, and imaging applications.

Main Results:

• Metal complexes offer diverse strategies to enhance EGFR-targeted cancer therapy.
• Ruthenium (Ru) and Platinum (Pt) complexes are designed for dual or multiple targeting.
• Gold (Au) complexes aim to overcome drug resistance, Cobalt (Co) complexes act as hypoxia-activated prodrugs, and Rhodium (Rh) and Iron (Fe) enhance anticancer effects.
• Gallium (Ga) complexes show potential for nuclear imaging tracer development.

Conclusions:

• Combining metals with EGFR inhibitors is a promising strategy to develop novel anticancer drugs.
• Metal complexes can address limitations of current EGFR-TKIs, offering improved efficacy, targeting, and reduced toxicity.
• This review highlights the significant progress and potential of metal-based EGFR-TKI complexes in oncology.